Onset and Outcomes of Immune-related Adverse Events in Genitourinary Cancer Treated With Immune Checkpoint Inhibitors

Immune-related adverse events showed distinct incidence and prognostic relevance between urothelial and renal cell carcinoma. These findings underscore the need for treatment-specific monitoring and provide practical insights into managing toxicities and decisions regarding immunotherapy rechallenge.